Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

NCT02016872 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Non-Small-Cell-Lung Cancer (NSCLC)

Interventions

DRUG: 18F-FMISO
OTHER: PET/CT

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]